MNPR

Monopar Therapeutics Stock Analysis

AI Rating

Low
  • Quality3/10
  • Growth↓ 0/10
  • Momentum↑ 6/10
Monopar Therapeutics sales and earnings growth
MNPR Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -100.00%
  • FCF Y/Y↓ -81.96%
Monopar Therapeutics gross and profit margin trends
MNPR Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -155.60%
Monopar Therapeutics net debt vs free cash flow
MNPR Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Monopar Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗